Skip to main content
OpenTrials
Completed

NCT Number: NCT01056770

Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers

The currently available stock of smallpox vaccine would be insufficient in the face of an incident of smallpox attack. Thus, new manufacturing methods for smallpox vaccine are urgently needed because previous manufacturing methods using calf lymph are no longer acceptable in the view of current standards. Recently, CJ corporation in Republic of Korea has developed cell-culture derived smallpox vaccine (CJ-50300) which was manufactured by infecting MRC-5 cells. The aim of this clinical trial were to assess safety, reactogenicity, and immunogenicity of CJ-50300.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Seoul National University Hospital

Seoul, 110-744, South Korea

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy Korean male and female subjects between 19 and 60 years of age at the time of screening visit
  • Willing to participate and have signed the informed consent form
  • In good general health, without clinically skin diseases history, physical examination or laboratory test results
  • Hematocrit > 33% for women; > 38% for men
  • White cell count 3,300-12,000/mm3
  • Total lymphocyte count > 800 cells/mm3

Exclusion criteria

  • Subjects who have been vaccinated with smallpox vaccines
  • Diseases or conditions that cause immunodeficiency (For examples; HIV AIDS, leukemia, lymphoma, generalized malignancy, agammaglobulinemia, history of transplantation, therapy with alkylating agents, antimetabolites, radiation, or oral or parenteral corticosteroids, basal cell carcinoma, liver cirrhosis or advanced liver disease).
  • In close physical contact (household or at work) with an individual who has the diseases or conditions that cause immunodeficiency
  • History or present of eczema or atopic dermatitis
  • Allergy or sensitivity to any known components of vaccine or other medicines
  • In close physical contact (household or at work) with an individual who has acute or chronic skin conditions such as dermatitis, exfoliative dermatitis
  • Subjects who have taken corticosteroid within 3 months of vaccination or who are taking oral or parenteral corticosteroid.
  • Subjects who have been taken immunosuppressive therapy including interferon within 3 months of vaccination or are taking immunosuppressive therapy.
  • Subjects who are planning for blood donations
  • Autoimmune disease such as lupus erythematosus
  • Subjects who work in medical institution
  • Household contacts with women who are pregnant or breast-feeding
  • Female subjects who are pregnant or breast-feeding and have positive result by serum pregnancy test or urine pregnancy test, or do not using approved contraceptives such as sterilization, contraceptive ring injectable, combined oral contraceptive pills and barrier contraceptive, combined hormone-based therapy, contraceptive cream, contraceptive jelly, diaphragm or condoms
  • Subjects household member < 1 year old or work with children < 1 year old
  • Subjects with a known history of Cardiac disease or have three or more of the following risk factors: hyperpiesia, obesity, hyperlipidemia, glucosuria, sclerosis, cerebral arteriosclerosis
  • Receipt of immunoglobulin or vaccine within 4 weeks of vaccination
  • Subjects who are allergic to latex, inflammatory opthalmic disease, or taking antiviral agents.
  • Receipt of investigational research agents within 4 months of vaccination
  • HBsAg seropositive
  • HCV antibody seropositive
  • HIV seropositive
  • Subjects having fever (oral temperature > 38℃) or severe nutrition disorder
  • Blood donation within 3 months since screening visit
  • Subject who are not suitable to participate in study according to investigator's judgement

Treatment and study plan

smallpox vaccine CJ-50300

Drug

Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination

Other names: CJ-53300

Primary outcomes

  1. Pocket formation

    Time frame: 7-9 day

  2. Adverse reactions

    Time frame: 0-28 days

Secondary outcomes

  1. Antibody response

    Time frame: 14 or 28 days

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Collaborators

  • HK inno.N Corporation

Registry information

Official study title

An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Vaccinia-naive Healthy Volunteers

Important dates

Study start
2009
Primary completion
2010
Study completion
2011
First posted
Jan 26, 2010
Registry last updated
Dec 6, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.